Key facts
- This page summarizes David Norman Cade's Form 3 filing for Telix Pharmaceuticals Ltd (TLX).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2026, 07:25.
David Norman Cade - 18 Mar 2026 Form 3 Insider Report for Telix Pharmaceuticals Ltd (TLX)
- Reporting relationship
- Group Chief Medical Officer
- Issuer ticker
- TLX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Oliver Newman, on behalf of Dr. David Cade, Group CMO
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
David Norman Cade filed Form 3 for Telix Pharmaceuticals Ltd (TLX) on 01 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002123007
Primary reporting owner
Cade David Norman
- Relationship
- Group Chief Medical Officer
- Address
- C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
- Signature
- /s/ Oliver Newman, on behalf of Dr. David Cade, Group CMO
- Signature date
- 01 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 373,133
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLX
holding
Derivative
Performance Share Appreciation Rights (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 78,189
- Exercise price
- $4.95
- Footnotes
- F1, F2
TLX
holding
Derivative
Performance Share Appreciation Rights (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 84,293
- Exercise price
- $6.90
- Footnotes
- F2, F3
TLX
holding
Derivative
Share Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,080
- Exercise price
- $0.000000
- Footnotes
- F4
TLX
holding
Derivative
Share Rights
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 11,486
- Exercise price
- $0.000000
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
he performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and exercisable on March 6, 2025
Footnote F2
Conversion price is reported in Australian Dollars.
Footnote F3
The PSARs were granted on April 25, 2023, and became vested and exercisable on March 12, 2026.
Footnote F4
The share rights (SRs) were granted on January 1, 2025, and became vested and exercisable on March 5, 2026.
Footnote F5
The SRs were granted on March 18, 2026 and will become vested and exercisable in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only, subject to continued service with the issuer. The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share.
SEC remarks
Ex. 24 - Power of Attorney